The lede: Everyone prices Vertex Pharmaceuticals (VRTX) as a biotech, waiting on the next trial readout. That's the wrong model. Vertex's cystic fibrosis franchise (Trikafta, Alyftrek) isn't a market position — it's a regulatory one, built on orphan-drug exclusivity and a functional monopoly over the only disease-modifying CF therapy that exists. Now the same regulatory logic is being applied to its second act. Journavx (suzetrigine), Vertex's first-in-class non-opioid pain drug approved by the FDA in January 2025, carries no DEA schedule — a classification decision, not a lab result. That single fact triggers the NOPAIN Act, which requires CMS to pay hospitals and surgery centers a separate, unbundled Medicare reimbursement for qualifying non-opioid post-surgical drugs through 2027. Translation: Washington is using scheduling status and reimbursement plumbing — not efficacy data — to steer tens of thousands of surgical claims a day toward Vertex's drug. That's a policy moat, and it compounds.